The obesity epidemic and its cardiovascular consequences

Current Opinion in Cardiology

Volumn 21, Issue 4, 2006, Pages 353-360

  Behn, Agnieszka ^a   Ur, Ehud ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b 7 North Victoria Building ^*  (Canada)

Author keywords

Body mass index; Cardiovascular disease; Cardiovascular mortality; Metabolic syndrome; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

BODY FAT DISTRIBUTION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; INSOMNIA; INSULIN SYNTHESIS; LIVER TOXICITY; METABOLIC SYNDROME X; MORTALITY; NAUSEA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VOMITING; WORLD HEALTH ORGANIZATION;

APPETITE DEPRESSANTS; BODY FAT DISTRIBUTION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LACTONES; LIFE STYLE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES; THIAZOLIDINEDIONES; WAIST-HIP RATIO;

EID: 33748105168     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000231406.84554.96     Document Type: Review

References (72)

1. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: WHO; 1999.
2. Flegal JN, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults. JAMA 2002; 288:1723-1727.
3. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286:1195-1200.
4. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999; 283:1530-1538.
5. Yan LL, Daviglus ML, Liu K, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006; 295:190-198.
6. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States. JAMA 2004; 291:1238-1245.
7. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293:1861-1867.
8. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293:1868-1874.
9. Willett WC, Hu FB, Colditz GA, Manson JE. Underweight, overweight, obesity, and excess deaths. JAMA 2005; 294:551.
10. Strickler HD, Hall C, Wylie-Rosett J, Rohan T. Underweight, overweight, obesity, and excess deaths. JAMA 2005; 294:551-552.
11. Ding EL. Underweight, overweight, obesity, and excess deaths. JAMA 2005; 294:552.
12. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group, Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
13. James WPT, Jackson-Leach R, Ni Mhurchu C, et al. Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors, Vol. 1, Geneva: WHO; 2004. pp. 497-596.
14. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352:1138-1145.
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
16. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
17. Hunt KJ, Resendez WK, Haffner SM, Stern MP. National Cholesterol Education Program vs. World Health Organization metabolic syndrome in relation to all cause and cardiovascular mortality in San Antonio Heart Study. Circulation 2004; 110:1251-1257.
18. Meigs JB, Wilson PW, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52:2160-2167.
19. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006;21:1-6.
20. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
21. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245-1250.
22. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-141.
23. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
24. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005; 28:2745-2749.
25. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
26. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-1649. Case-control study of over 27 000 patients in 52 countries assessing which measure of obesity is the best predictor of myocardial infarction. The waist-to-hip ratio showed the strongest relation with the risk of myocardial infarction compared to BMI, waist and hip measurements across both sexes, all ages and ethnic groups.
27. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25:1177-1184.
28. Lakka HM, Lakka TA, Tuomilehto J, et al. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160:1160-1168.
29. Hedblad B, Nilsson P, Engström G, et al. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002; 19:470-475.
30. Després JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957.
31. Lempiäinen P, Mykkänen L, Pyörälä K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100:123-128.
32. Hu G, Qiao Q, Tuomilehto J, et al., DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 2004; 47:1245-1256.
33. Cheal KL, Abbasi F, Lamendola C, et al. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004; 53:1195-1200.
34. Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, et al. Identification of subjects with insulin resistance and β-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003; 52:2740-2747.
35. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
36. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327-334.
37. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
38. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8 year follow up of 14,719 initially healthy American women. Circulation 2003; 107:391-397.
39. Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107:645-651.
40. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
41. Chandran M, Phillips SA, Ciaraldi T. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26:2442-2450.
42. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003; 348:2136-2137.
43. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144:2195-2200.
44. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92:347-355.
45. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935.
46. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730-1737.
47. Rosicka M, Krsek M, Matoulek M, et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptor levels. Physiol Res 2003; 52:61-66.
48. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001; 104:3052-3056.
49. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
50. Youn BS, Yu KY, Park HU, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89:150-156.
51. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004; 6:163-170.
52. Bravata DM, Sanders L, Huang J, et al. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 2003; 289:1837-1850.
53. Samaha FF, Iqbal N, Seshadri P, et al. A low carbohydrate as compared with low fat diet in severe obesity. N Engl J Med 2003; 348:2074-2081.
54. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348:2057-2058.
55. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
56. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
57. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
58. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferatoractivated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99:2416-2422.
59. Murphy EJ, Davern TJ, Shakil AO, et al., Acute Liver Failure Study Group. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci 2000; 45:549-553.
60. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
61. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27:2654-2660.
62. Dormandy JA, Charbonnel B, Eckland DJA. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366:1279-1289. Over 5000 patients with extensive macrovascular disease were randomized to pioglitazone or placebo. A small relative risk reduction in the secondary composite endpoint was found in patients treated with pioglitazone but perhaps due to improvement in lipid profile, A1c and blood pressure.
63. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547-1554.
64. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532-546.
65. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353:2111-2120. A 1-year trial of obese adults (BMI 38 kg/m2) comparing sibutramine and lifestyle modification. The combination of medication and lifestyle modification resulted in the greatest weight loss.
66. Torgerson JS, Hauptman J, Boldrin MN. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004; 27:155-161.
67. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3:771-784.
68. Van Gaal LF, Rissanen AM, Scheen AJ, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397. A 1-year trial demonstrated that rimonabant compared with placebo resulted in significantly greater weight loss, reduction in waist circumference, lipid profile, insulin resistance and prevalence of the metabolic syndrome.
69. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through regulation of lipolysis and energy balance. FASEB J 2005; 19:1567-1569.
70. Despres JP, Golay A, Sjostrom L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134. Over 1000 overweight and obese patients with dyslipidemia were randomized to either rimonabant or placebo. At 1 year patients treated with rimonabant had significantly greater weight loss, reduction in waist circumference, lipid profile and increase in adiponectin levels.
71. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 2005; 365:1363-1364.
72. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2005; 295:761-775. The RIO trial (RIO-North America) confirmed the efficacy of rimonabant but also evaluated the long-term effectiveness. After 1 year, rimonabant treated patients were re-randomized to receive placebo or continue on the same rimonabant dose. Patients who were switched from the rimonabant group to placebo regained the weight lost but patients who continued on rimonabant maintained their weight loss.